Biopharma company M&A transaction volumes by type US Europe 2010-2019

In 2019, trade sales of venture capital-backed contingent biopharma companies had a transaction volume of approximately 9.6 billion U.S. dollars. This statistic depicts the M&A transaction volumes of trade sales of private U.S. and European biopharma companies from 2010 to 2019, by company type.

M&A transaction volumes of private U.S. and European biopharma companies 2010 to 2019, by type (in billion U.S. dollars)

Characteristic	VC- backed upfront	VC- backed contingent	PE- backed	Other private
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-
-	-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

February 2020

More information

Region

Europe, United States

Survey time period

2010 to 2019

Supplementary notes

Completed trade sales of private U.S. and European biopharma companies, not including asset deals or purchases of divisions. "VC": venture capital; "PE": private equity. “Other private companies” are companies not majority-owned by venture or private equity investors.
* Values for "other private" and "PE-backed" companies not stated in original document.

Citation formats